PTGX$141.051.20%1.675
Protagonist Therapeutics Inc (PTGX)
Date: 2026-11-03 16:00O: 140.73H: 144.27L: 140.54C: 141.05Vol: 176.2k
Protagonist Therapeutics Inc stock is traded at $141.05, with a volume of 200,417. It is up +1.20% in the last 24 hours and up +0.70% over the past month. Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Previous Close:
$139.37
Open:
$140.73
24h Volume:
200,417
Relative Volume:
0.35
Market Cap:
$9.13B
Revenue:
$74.06M
Net Income/Loss:
-$114.71M
P/E Ratio:
-
EPS:
-$1.80
Net Cash Flow:
-$117.90M
1W Performance:
-0.05%
1M Performance:
+0.70%
6M Performance:
+43.38%
1Y Performance:
+85.71%
1-Day Range:
$140.54$144.27
1-Week Range:
$138.29$146.44
52-Week Range:
$75.44$160.81
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(510) 474-0170Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
- Ali AsifSep 30 '26Chief Financial Officer
- Transaction
- Option Exercise
- Cost
- $23.72
- #Shares
- 58,629
- Value ($)
- 1,390,735
- #Shares Total
- 117,632
- Ali AsifSep 30 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $141.78
- #Shares
- 58,629
- Value ($)
- 8,312,294
- #Shares Total
- 59,003
- ASIF ALISep 30 '26Officer
- Transaction
- Proposed Sale
- Cost
- $140.97
- #Shares
- 58,629
- Value ($)
- 8,264,930
- #Shares Total
- 0
- PATEL DINESH V PH DSep 10 '26President and CEO
- Transaction
- Sale
- Cost
- $144.10
- #Shares
- 7,278
- Value ($)
- 1,048,760
- #Shares Total
- 522,968
- PATEL DINESH V PH DSep 10 '26President and CEO
- Transaction
- Option Exercise
- Cost
- $21.58
- #Shares
- 7,278
- Value ($)
- 157,059
- #Shares Total
- 530,246
- PATEL DINESH V PH DSep 09 '26President and CEO
- Transaction
- Option Exercise
- Cost
- $21.58
- #Shares
- 63,548
- Value ($)
- 1,371,366
- #Shares Total
- 586,516
- PATEL DINESH V PH DSep 09 '26President and CEO
- Transaction
- Sale
- Cost
- $146.18
- #Shares
- 63,548
- Value ($)
- 9,289,447
- #Shares Total
- 522,968
- PATEL DINESH V PH DSep 08 '26President and CEO
- Transaction
- Sale
- Cost
- $145.87
- #Shares
- 54,174
- Value ($)
- 7,902,361
- #Shares Total
- 522,968
- PATEL DINESH V PH DSep 08 '26President and CEO
- Transaction
- Option Exercise
- Cost
- $21.58
- #Shares
- 54,174
- Value ($)
- 1,169,075
- #Shares Total
- 577,142
- PATEL DINESH V PH DAug 11 '26President and CEO
- Transaction
- Sale
- Cost
- $148.52
- #Shares
- 34,239
- Value ($)
- 5,085,176
- #Shares Total
- 523,478
